[心力衰竭:ESC 2023指南的更新]。

IF 1.1 4区医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Herz Pub Date : 2024-02-01 Epub Date: 2023-11-14 DOI:10.1007/s00059-023-05221-2

Johann Bauersachs, Samira Soltani

{"title":"[心力衰竭:ESC 2023指南的更新]。","authors":"Johann Bauersachs, Samira Soltani","doi":"10.1007/s00059-023-05221-2","DOIUrl":null,"url":null,"abstract":"The 2023 update of the European Society of Cardiology (ESC) guidelines recommends (class IA) the administration of sodium-glucose transporter 2 inhibitors (SGLT2i) also for patients with heart failure with preserved ejection fraction (HFpEF) and mildly reduced EF (HFmrEF). Thus, SGLT2i are the only medication that should be given to all heart failure patients for improvement of prognosis independent of left ventricular EF. The rapid administration of the fantastic four drugs and their prompt titration after a heart failure decompensation is now included in the guidelines with a class IB recommendation. For patients with reduced EF (HFrEF) or HFmrEF and iron deficiency there is now a class IIa recommendation for intravenous administration of ferric carboxymaltose or ferric derisomaltose.","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"19-21"},"PeriodicalIF":1.1000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Heart failure: update of the ESC 2023 guidelines].\",\"authors\":\"Johann Bauersachs, Samira Soltani\",\"doi\":\"10.1007/s00059-023-05221-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The 2023 update of the European Society of Cardiology (ESC) guidelines recommends (class IA) the administration of sodium-glucose transporter 2 inhibitors (SGLT2i) also for patients with heart failure with preserved ejection fraction (HFpEF) and mildly reduced EF (HFmrEF). Thus, SGLT2i are the only medication that should be given to all heart failure patients for improvement of prognosis independent of left ventricular EF. The rapid administration of the fantastic four drugs and their prompt titration after a heart failure decompensation is now included in the guidelines with a class IB recommendation. For patients with reduced EF (HFrEF) or HFmrEF and iron deficiency there is now a class IIa recommendation for intravenous administration of ferric carboxymaltose or ferric derisomaltose.\",\"PeriodicalId\":12863,\"journal\":{\"name\":\"Herz\",\"volume\":\" \",\"pages\":\"19-21\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Herz\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00059-023-05221-2\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Herz","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00059-023-05221-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/14 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

2023年更新的欧洲心脏病学会(ESC)指南推荐(IA类)钠-葡萄糖转运蛋白2抑制剂(SGLT2i)也适用于射血分数保留(HFpEF)和EF轻度降低(HFmrEF)的心力衰竭患者。因此，SGLT2i是所有心力衰竭患者改善预后的唯一药物，与左室EF无关。在心力衰竭失代偿后，快速给药这四种神奇药物并及时滴药，现在已被列入指南的IB级推荐。对于EF降低(HFrEF)或HFmrEF和缺铁的患者，现在推荐静脉注射三羧基麦芽糖铁或三异麦芽糖铁。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

[Heart failure: update of the ESC 2023 guidelines].

The 2023 update of the European Society of Cardiology (ESC) guidelines recommends (class IA) the administration of sodium-glucose transporter 2 inhibitors (SGLT2i) also for patients with heart failure with preserved ejection fraction (HFpEF) and mildly reduced EF (HFmrEF). Thus, SGLT2i are the only medication that should be given to all heart failure patients for improvement of prognosis independent of left ventricular EF. The rapid administration of the fantastic four drugs and their prompt titration after a heart failure decompensation is now included in the guidelines with a class IB recommendation. For patients with reduced EF (HFrEF) or HFmrEF and iron deficiency there is now a class IIa recommendation for intravenous administration of ferric carboxymaltose or ferric derisomaltose.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Herz 医学-心血管系统

CiteScore

3.00

自引率

5.90%

发文量

审稿时长

4-8 weeks

期刊介绍： Herz is the high-level journal for further education for all physicians interested in cardiology. The individual issues of the journal each deal with specific topics and comprise review articles in English and German written by competent and esteemed authors. They provide up-to-date and comprehensive information concerning the speciality dealt with in the issue. Due to the fact that all relevant aspects of the pertinent topic of an issue are considered, an overview of the current status and progress in cardiology is presented. Reviews and original articles round off the spectrum of information provided.